[1]
|
Luo, J., Li, Y., Chen, J., Qiu, H., Chen, W., Luo, X., Chen, Y., Tan, Y. and Li, J. (2023) Evaluating the Role of Serum Uric Acid in the Risk Stratification and Therapeutic Response of Patients with Pulmonary Arterial Hypertension Asso-ciated with Congenital Heart Disease (PAH-CHD). Frontiers in Pharmacology, 14, Article 1238581.
https://doi.org/10.3389/fphar.2023.1238581
|
[2]
|
中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版) [J]. 中华医学杂志, 2021, 101(1): 11-51. https://doi.org/10.3760/Cma.J.Cn112137-20201008-02778
|
[3]
|
Parikh, K.S., Rajagopal, S., Arges, K., Ahmad, T., Sivak, J., Kaul, P., Shah, S.H., Tapson, V., Velazquez, E.J., Douglas, P.S. and Samad, Z. (2015) Use of Outcome Measures in Pulmonary Hypertension Clinical Trials. American Heart Journal, 170, 419-429.e3. https://doi.org/10.1016/j.ahj.2015.06.010
|
[4]
|
Rosenzweig, E.B., Abman, S.H., Adatia, I., Beghetti, M., Bonnet, D., Haworth, S., Ivy, D.D. and Berger, R.M.F. (2019) Paediatric Pulmonary Arterial Hypertension: Updates on Definition, Classification, Diagnostics and Management. European Respiratory Journal, 53, Article ID: 1801916. https://doi.org/10.1183/13993003.01916-2018
|
[5]
|
Lammers, A.E., Munnery, E., Hislop, A.A. and Haworth, S.G. (2010) Heart Rate Variability Predicts Outcome in Children with Pulmonary Arterial Hypertension. International Journal of Cardiology, 142, 159-165.
https://doi.org/10.1016/j.ijcard.2008.12.087
|
[6]
|
Douwes, J.M., Hegeman, A.K., Van Der Horst, M., et al. (2014) Six-Minute Walk-Test in Childhood Pulmonary Arterial Hypertension: Walking Distance and Decrease in Oxygen Saturation Provide Additional Prognostic Information. European Heart Journal, 35, 174-175.
|
[7]
|
Lammers, A.E., Diller, G.P., Odendaal, D., Tailor, S., Derrick, G. and Haworth, S.G. (2011) Comparison of 6-Min Walk Test Distance and Cardiopulmonary Exercise Test Performance in Children with Pulmonary Hypertension. Archives of Disease in Childhood, 96, 141-147. https://doi.org/10.1136/adc.2009.169904
|
[8]
|
Ploegstra, M.J., Douwes, J.M., Roofthooft, M.T., Zijlstra, W.M., Hillege, H.L. and Berger, R.M. (2014) Identification of Treatment Goals in Paediatric Pulmonary Arterial Hypertension. European Respiratory Journal, 44, 1616-1626.
https://doi.org/10.1183/09031936.00030414
|
[9]
|
Li, X.Y., Zheng, Y., Long, Y., Zhang, X., Zhang, L., Tian, D., Zhou, D. and Lv, Q.Z. (2017) Effect of Iloprost on Biomarkers in Patients with Congenital Heart Disease-Pulmonary Arterial Hypertension. Clinical and Experimental Pharmacology and Physiology, 44, 914-923. https://doi.org/10.1111/1440-1681.12796
|
[10]
|
Said, F., Haarman, M.G., Roofthooft, M.T.R., Hillege, H.L., Ploegstra, M.J. and Berger, R.M.F. (2020) Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children. The Journal of Pediatrics, 220, 139-145. https://doi.org/10.1016/j.jpeds.2020.01.001
|
[11]
|
Jin, N., Yu, M., Du, X., Wu, Z., Zhai, C., Pan, H., Gu, J. and Xie, B. (2023) Identification of Potential Serum Biomarkers for Congenital Heart Disease Children with Pulmonary Arterial Hypertension by Metabonomics. BMC Cardiovascular Disorders, 23, Article No. 167. https://doi.org/10.1186/s12872-023-03171-5
|
[12]
|
Hendriks, P.M., Van De Groep, L.D., Veen, K.M., Van Thor, M.C.J., Meertens, S., Boersma, E., Boomars, K.A., Post, M.C. and Van Den Bosch, A.E. (2022) Prognostic Value of Brain Natriuretic Peptides in Patients with Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. American Heart Journal, 250, 34-44.
https://doi.org/10.1016/j.ahj.2022.05.006
|
[13]
|
Li, X., Qiu, J., Pan, M., Zheng, D., Su, Y., Wei, M., Kong, X., Sun, W. and Zhu, J. (2015) Correlation between Congenital Heart Disease Complicated with Pulmonary Artery Hypertension and Circulating Endothelial Cells as Well as Endothelin-1. International Journal of Clinical and Experimental Pathology, 8, 10743-10751.
|
[14]
|
王雪芳, 余洁, 谢萍. 肺动脉高压的生物标志物[J]. 国际心血管病杂志, 2020, 47(1): 9-13.
|
[15]
|
Ploegstra, M.J. and Berger, R.M.F. (2021) Prognostic Biomarkers in Pediatric Pulmonary Arterial Hypertension. Cardiovascular Diagnosis and Therapy, 11, 1089-1101. https://doi.org/10.21037/cdt-20-374
|
[16]
|
Cerik, I.B., Dindas, F., Koyun, E., Dereli, S., Sahin, A., Turgut, O.O. and Gul, I. (2022) New Prognostic Markers in Pulmonary Arterial Hypertension: CRP to Albumin Ratio and Uric Acid. Clinical Biochemistry, 100, 22-28.
https://doi.org/10.1016/j.clinbiochem.2021.11.004
|
[17]
|
Moccaldi, B., De Michieli, L., Binda, M., Famoso, G., Depascale, R., Perazzolo, Marra, M., Doria, A. and Zanatta, E. (2023) Serum Biomarkers in Connective Tissue Dis-ease-Associated Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 24, Article 4178. https://doi.org/10.3390/ijms24044178
|
[18]
|
汪志新, 刘涛, 陈彩艳. 先天性心脏病合并肺动脉高压患儿血清H-FABP、NT-ProBNP、CTnI变化及临床意义[J]. 临床误诊误治, 2022, 35(9): 90-96.
|
[19]
|
韦依宁, 陈慧婉, 刘淑婷, 等. 血小板在肺动脉高压发生、发展中的作用及其机制[J]. 国际呼吸杂志, 2022, 42(19): 1491-1497. https://doi.org/10.3760/Cma.J.Cn131368-20220320-00211
|
[20]
|
Park, Y., Schoene, N. and Harris, W. (2002) Mean Platelet Volume as an Indicator of Platelet Activation: Methodological Issues. Platelets, 13, 301-306. https://doi.org/10.1080/095371002220148332
|
[21]
|
Mese, T., Guven, B., Yilmazer, M.M., Karadeniz, C., Ozdemir, R. and Doksoz, O. (2018) Platelet Activation Markers in Children with Congenital Heart Disease Associated with Pulmonary Arterial Hypertension. Congenital Heart Disease, 13, 506-511. https://doi.org/10.1111/chd.12616
|
[22]
|
Awad, A., Elnemr, S., Hodeib, H. and El Amrousy, D. (2022) Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Pe-diatric Cardiology, 43, 1264-1270.
https://doi.org/10.1007/s00246-022-02847-7
|
[23]
|
Arslan, D., Cimen, D., Guvenc, O., Kaya, F., Sert, A. and Oran, B. (2013) Platelet Distribution Width and Mean Platelet Volume in Children with Pulmonary Arterial Hypertension Secondary to Congenital Heart Disease with Left-to- Right Shunt: New Indices of Severity? Pediatric Cardiology, 34, 1013-1016.
https://doi.org/10.1007/s00246-012-0600-5
|
[24]
|
Trygve, S., Ellingsen, T.S., et al. (2017) Red Cell Distribution Width Is Associated with Future Risk of Incident Stroke. Thrombosis and Haemostasis, 115, 126-134.
|
[25]
|
余洪, 汪云鑫, 李品慧, 等. 急性ST段抬高性心肌梗死红细胞分布宽度血小板比率的变化及其与远期心血管事件的关系[J]. 中华保健医学杂志, 2020, 22(3): 150-153.
|
[26]
|
朱志勇. 红细胞分布宽度在先天性心脏病相关肺动脉高压患儿病情评估中的临床应用价值[J]. 中西医结合心脑血管病杂志, 2020, 18(1): 131-133.
|
[27]
|
Zuk, M., Migdal, A., Dominczak, J. and Brzezinska-Rajszys, G. (2019) Usefulness of Red Cell Width Distribution (RDW) in the Assessment of Children with Pulmonary Arterial Hypertension (PAH). Pediatric Cardiology, 40, 820- 826. https://doi.org/10.1007/s00246-019-02077-4
|
[28]
|
Smadja, D.M., Gaussem, P., Mauge, L., Israël-Biet, D., Dignat-George, F., Peyrard, S., Agnoletti, G., Vouhé, P.R., Bonnet, D. and Lévy, M. (2009) Circulating Endothelial Cells: A New Candidate Biomarker of Irreversible Pulmonary Hypertension Secondary to Congenital Heart Disease. Circulation, 119, 374-381.
https://doi.org/10.1161/CIRCULATIONAHA.108.808246
|
[29]
|
Budhiraja, R., Tuder, R.M. and Hassoun, P.M. (2004) Endothelial Dysfunction in Pulmonary Hypertension. Circulation, 109, 159-165. https://doi.org/10.1161/01.CIR.0000102381.57477.50
|
[30]
|
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R.P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W.P. and Stewart, D.J. (1993) Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. The New England Journal of Medicine, 328, 1732-1739. https://doi.org/10.1056/NEJM199306173282402
|
[31]
|
Rubens, C., Ewert, R., Halank, M., Wensel, R., Orzechowski, H.D., Schultheiss, H.P. and Hoeffken, G. (2001) Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated with the Severity of Primary Pulmonary Hypertension. Chest, 120, 1562-1569. https://doi.org/10.1378/chest.120.5.1562
|
[32]
|
Latus, H., Karanatsios, G., Basan, U., Salser, K., Müller, S., Khalil, M., Kreuder, J., Schranz, D. and Apitz, C. (2016) Clinical and Prognostic Value of Endothelin-1 and Big Endothelin-1 Expression in Children with Pulmonary Hypertension. Heart, 102, 1052-1058. https://doi.org/10.1136/heartjnl-2015-308743
|
[33]
|
张志芳, 屈小会. 内皮抑素、血小板反应蛋白-1水平与慢性心力衰竭的关系研究[J]. 临床医学研究与实践, 2022, 7(27): 15-18. https://doi.org/10.19347/J.Cnki.2096-1413.202227004
|
[34]
|
Daly, C.M., Griffiths, M., Simpson, C.E., Yang, J., Damico, R.L., Vaidya, R.D., Williams, M., Brandal, S., Jone, P.N., Polsen, C., Ivy, D.D., Austin, E.D., Nichols, W.C., Pauciulo, M.W., Lutz, K., Nies, M.K., Rosenzweig, E.B., Hirsch, R., Yung, D. and Everett, A.D. (2021) Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Journal of the American Heart Association, 10, e021409.
https://doi.org/10.1161/JAHA.120.021409
|
[35]
|
Simpson, C.E., Griffiths, M., Yang, J., Nies, M.K., Vaidya, R.D., Brandal, S., Martin, L.J., Pauciulo, M.W., Lutz, K.A., Coleman, A.W., Austin, E.D., Ivy, D.D., Nichols, W.C., Everett, A.D., Hassoun, P.M. and Damico, R.L. (2021) The Angiostatic Peptide Endostatin Enhances Mortality Risk Prediction in Pulmonary Arterial Hypertension. ERJ Open Research, 7, 00378-2021. https://doi.org/10.1183/23120541.00378-2021
|
[36]
|
孙玉双, 李姗姗. MicroRNA在肺动脉高压病理机制中的研究进展[J]. 国际遗传学杂志, 2021, 44(2): 117-123.
https://doi.org/10.3760/Cma.J.Cn231536-20201026-00107
|
[37]
|
Long, L., Xiao, Y., Yin, X., Gao, S., Zhou, L. and Liu, H. (2020) Expression of Serum MiR-27b and MiR-451 in Patients with Congenital Heart Disease Associated Pulmonary Artery Hypertension and Risk Factor Analysis. Experimental and Therapeutic Medicine, 20, 3196-3202. https://doi.org/10.3892/etm.2020.9042
|
[38]
|
罗俊, 苏威, 朱腾腾, 等. 先天性心脏病相关性肺动脉高压患者血清高迁移率组蛋白B1变化及其临床意义[J]. 中国实用内科杂志, 2018, 38(4): 364-369. https://doi.org/10.19538/J.Nk2018040114
|
[39]
|
Huang, Y.Y., Su, W., Zhu, Z.W., Tang, L., Hu, X.Q., Zhou, S.H., Fang, Z.F. and Li, J. (2016) Elevated Serum HMGB1 in Pulmonary Arterial Hypertension Secondary to Congenital Heart Disease. Vascular Pharmacology, 85, 66-72. https://doi.org/10.1016/j.vph.2016.08.009
|
[40]
|
曾晓春, 伍伟锋, 黄凯. 先天性心脏病肺动脉高压与外周血存活素的关系[J]. 实用医学杂志, 2010, 26(17): 3140- 3141.
|
[41]
|
Blanco, I., Marquina, M., Tura-Ceide, O., Ferrer, E., Ramírez, A.M., Lopez-Meseguer, M., Callejo, M., Perez-Viz- caino, F., Peinado, V.I. and Barberà, J.A. (2023) Survivin Inhibition with YM155 Ameliorates Experimental Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 14, Article ID: 1145994.
https://doi.org/10.3389/fphar.2023.1145994
|
[42]
|
Li, G., Zhang, H., Zhao, L., Zhang, Y., Yan, D., Liu, Y., Su, J. and Fan, X. (2019) The Expression of Survivin in Irreversible Pulmonary Arterial Hypertension Rats and Its Value in Evaluating the Reversibility of Pulmonary Arterial Hypertension Secondary to Congenital Heart Disease. Pulmonary Circulation, 9, 1-11.
https://doi.org/10.1177/2045894019859480
|